Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022

Copenhagen, Denmark, 6 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the Principal Investigator, Chief Surgeon Jane Skjøth-Rasmussen will be presenting the outstanding clinical data from the completed phase I/IIa trial with FG001 in patients with aggressive brain cancer undergoing surgery at the European Congress of Neurosurgery on 19 October 2022 in Belgrade, Serbia.

The excellent phase l/lla clinical data of FG001 in aggressive brain cancer will be presented by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen at the European Congress of Neurosurgery in Belgrade, facilitated by the European Association of Neurosurgical Societies (EANS).

The purpose of the trial was to investigate FG001 for intraoperative visualization of malignant glioma in patients scheduled for neurosurgery. The full abstract can be found here.

Based on the promising clinical data, FG001 is advanced into a phase IIb trial in aggressive brain cancer where the top line result is expected in H1 2023.